



FOR IMMEDIATE RELEASE

June 20, 2016

AbbVie GK
Eisai Co., Ltd.
EA Pharma Co., Ltd.

AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing

rheumatoid arthritis, plaque psoriasis, arthropathic psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis).

AbbVie, Eisai and EA Pharma will continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.

[Notes to editors]

1. About Humira

HUMIRA® is a fully human anti TNF monoclonal antibody which is approved for the following indications in Japan: "treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following .43170TD0Tc0003TjET1g69.4260oie,

approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly